Mitchell Shirvan

Chief Scientific and Development Officer · Silexion Therapeutics · company speakers →

Dr. Shirvan has over 25 years of industry experience. Previously served as Senior Vice President of R&D at Foamix Pharmaceuticals Ltd., CEO at Macrocure Ltd., and held various positions at Teva Pharmaceutical Industries. He was a research fellow at the U.S. National Institutes of Health and holds a Ph.D. in microbiology from The Hebrew University of Jerusalem and an MBA from the University of Bradford.

Is this you? Claim this profile →

No public contact links on file.

Speaking history

RAS-Targeted Drug Development Summit

8 September 2026 Boston, United States “SIL204, an Isoform-Selective Pan-KRAS Silencing Stable siRNA with Dual-Delivery Administration for Pancreatic Cancer: Phase 2 Early Safety Findings & Supporting Preclinical Data”

Sourcing speakers for your event?

Browse the speaker directory →